For HER2-positive gastric cancer patients, although combination therapy with trastuzumab and chemotherapy provides meaningful survival benefit [13], many clinical trials targeting HER2 have failed to demonstrate clinical benefits in subsequent-line treatment [21,22,23]. This evidence concerns the gene ERBB2 and gastric cancer.